Results from Biogrid:
NBCSP versus symptomatic cancers by stage (1/5/06- 30/4/09):
For stage analysis the 121 patients that were diagnosed by FOBT but not as part of the National Bowel Cancer Screening Program (NBCSP) were excluded. Therefore the following stage analysis is of NBCSP vs symptomatic presentation only. The total number of patients looked at was 2165.
| Stage |
NBCSP |
Symptomatic |
Total |
| A |
39 (41%) |
346 (18%) |
385 |
| B |
25 (26%) |
662 (36%) |
687 |
| C |
23 (24%) |
513 (28%) |
536 |
| D |
8 (9%) |
320 (18%) |
328 |
| Total |
95 (4.9%) |
1841 (95.1%) |
1936 (100%) |
Missing=229
P<0.001
Graph of NBCSP versus symptomatic cancers according to stage at diagnosis.
The NBCSP has so far had a measurable impact with 4.7% (95 /2286) of all colorectal cancers being diagnosed as a result of the NBCSP despite it only being offered to select age groups.
(Total number of patients used in this analysis = 2286).
About Biogrid
www.biogrid.org.au/wps/portal
BioGrid is a unique platform for life science research teams to access and share genetic and
clinical research data across multiple organisations in an ethically approved and secure way,
using the World Wide Web.
Data source: Bi-National Colorectal Cancer Audit. This is collaboration being led by The Colorectal Surgical Society of Australia and New Zealand (CSSANZ) with The Royal Australasian College of Surgeons (RACS) and BioGrid Australia.